2.43
price down icon2.02%   -0.05
after-market After Hours: 2.43
loading
Erasca Inc stock is traded at $2.43, with a volume of 4.90M. It is down -2.02% in the last 24 hours and up +56.77% over the past month. Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$2.48
Open:
$2.52
24h Volume:
4.90M
Relative Volume:
3.78
Market Cap:
$689.32M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-2.9634
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+9.95%
1M Performance:
+56.77%
6M Performance:
+129.25%
1Y Performance:
-3.57%
1-Day Range:
Value
$2.41
$2.765
1-Week Range:
Value
$2.125
$2.765
52-Week Range:
Value
$1.01
$3.305

Erasca Inc Stock (ERAS) Company Profile

Name
Name
Erasca Inc
Name
Phone
(858) 465-6511
Name
Address
3115 MERRYFIELD ROW, SAN DIEGO
Name
Employee
129
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ERAS's Discussions on Twitter

Compare ERAS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ERAS
Erasca Inc
2.43 703.50M 0 -125.04M -122.99M -0.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.15 105.19B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
450.68 60.24B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.86 61.82B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
798.94 49.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
351.09 37.52B 4.56B -176.77M 225.30M -1.7177

Erasca Inc Stock (ERAS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-03-25 Downgrade BofA Securities Buy → Underperform
Aug-18-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-26-25 Initiated Raymond James Outperform
Nov-18-24 Initiated Jefferies Buy
Mar-11-24 Initiated CapitalOne Overweight
Jan-05-24 Downgrade BofA Securities Buy → Neutral
Oct-11-23 Initiated H.C. Wainwright Buy
Mar-30-23 Initiated Mizuho Buy
Feb-24-23 Initiated Goldman Buy
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
View All

Erasca Inc Stock (ERAS) Latest News

pulisher
Oct 06, 2025

Will Erasca Inc. price bounce be sustainableIndex Update & Accurate Entry/Exit Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Why Erasca Inc. stock remains on buy lists2025 Year in Review & Fast Gain Stock Trading Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Erasca Inc. stock benefit from upcoming earnings reportsJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Can swing trading help recover from Erasca Inc. losses2025 Price Momentum & Community Driven Trade Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why retail investors favor Erasca Inc. stockMarket Performance Summary & Weekly High Conviction Ideas - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Erasca: Hype Building Into The End Of The Year (Rating Downgrade) (NASDAQ:ERAS) - Seeking Alpha

Oct 03, 2025
pulisher
Oct 02, 2025

Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Oct 02, 2025
pulisher
Oct 02, 2025

Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 02, 2025
pulisher
Sep 28, 2025

What drives Erasca Inc stock priceMarket Rumors and News & High Return Stock Ideas - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

Erasca Inc Stock Analysis and ForecastBreakout Stock Watch & Interactive Charts for Smarter Trading - earlytimes.in

Sep 28, 2025
pulisher
Sep 26, 2025

Erasca, Inc. (NASDAQ:ERAS) Receives $3.71 Consensus PT from Analysts - Defense World

Sep 26, 2025
pulisher
Sep 22, 2025

Key resistance and support levels for Erasca Inc.Weekly Profit Summary & AI Driven Stock Price Forecasts - newser.com

Sep 22, 2025
pulisher
Sep 21, 2025

Wall Street Zen Upgrades Erasca (NASDAQ:ERAS) to Hold - Defense World

Sep 21, 2025

Erasca Inc Stock (ERAS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$85.38
price down icon 2.05%
$23.34
price up icon 4.71%
$32.74
price up icon 0.31%
$106.28
price up icon 0.21%
$161.81
price down icon 0.31%
biotechnology ONC
$351.09
price up icon 2.77%
Cap:     |  Volume (24h):